Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
免疫療法薬アテゾリズマブ（テセントリク）と、がん細胞が成長する必要がある新しい血管の形成を防ぐ抗血管新生薬ベバシズマブを組み合わせる実験が進行中です。 ベバシズマブは子宮頸がんに対する有効な薬剤であり、ベバシズマブが免疫療法の有効性を向上させる可能性があるという前臨床データがあります。 したがって、これは子宮頸がんの興味深い組み合わせであり、私たちはこの研究の結果を心待ちにしています。
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
子宮頸がん免疫療法の研究はますます進んでおり、子宮頸がん患者に大きな希望を与えており、より良い治療効果が期待されています。
